A Reader Asks: She is 36-40 y.o. and Cycling Normally: What are the potential Benefits of Hormone Therapy?

Written by: Meredith Paci | Functional Health Coach

A female in her late thirties wrote into the anonymous question form asking two things: what are the actual benefits of hormone therapy (menopausal hormone therapy and TRT), and what delivery methods are available?

Before I get into the answers, I must be clear about what I do and do not know about her. She is between 36 and 40. She has a consistent menstrual cycle and her cycle length falls within a normal range of 21 to 35 days. She is not on hormonal birth control or any hormone therapy. She has had bloodwork done and reports that she understands her results. I have not seen those labs. I do not know her full clinical history, her symptom picture, her body composition, her stress load, her digestive function, her thyroid status, or the dozen other variables that would take this from a general educational answer to a specific clinical recommendation.

I am telling you this not as a disclaimer but because it is clinically relevant to the second half of this piece, where I bring the answer back to her. That said, Hi! My name is Meredith Paci if you aren’t aware and I am a co-founder of Fortify Health Coaching. I am not a licensed medical provider. The content of this post is educational and does not constitute medical advice or a patient-provider relationship….now, let's get to it!

The Case for Hormone Therapy: What the Research Actually Supports

The conversation around hormone therapy has been confused for decades, largely because of the Women's Health Initiative study published in 2002, which generated widespread fear around breast cancer and cardiovascular risk from HRT. It was a significant study and we gained a lot of information from it, but the findings were persistently misinterpreted and the headlines that followed caused disproportionate harm to women's access to care.I am not going to go deep into things BUT we do have a resource we created on just this study and the fear around hormone therapy that you can download for free [HERE]. The study used oral conjugated equine estrogens combined with medroxyprogesterone acetate, a synthetic progestin, not bioidentical hormones, and delivered them orally to women who were, on average, 63 years old and already years past menopause. The findings have been persistently misapplied generically in younger, perimenopause-adjacent women ever since.

The Menopause Society, formerly NAMS, along with a growing body of research from the last two decades, has substantially reframed the risk-benefit conversation even most recently the black box warning was finally removed from estrogen products. Here is what is well-supported in the current literature regarding BENEFITS of Hormones.

Estradiol

Estradiol is the primary and strongest estrogen (we have other types) produced during the reproductive years. When levels decline, the downstream effects are significant and extend well beyond hot flashes, which is still the primary symptom most clinicians wait for before having this conversation…so silly.

Bone density. Estradiol is the primary regulator of bone remodeling. Decline in estrogen is the driver of accelerated bone loss in the perimenopausal and postmenopausal transition.

Cardiovascular health. The timing hypothesis, now well-established, holds that estrogen therapy initiated within ten years of menopause or before age 60 is associated with cardiovascular protection, not harm. But please do not sensationalize this statement… protective is not synonymous with “just using estradiol solo will prevent any cardiovascular disease or event ever happening”... I did not say that. I said it is a real force regarding being protective. Let me explain. Estradiol supports endothelial function, lipid profiles, and vascular tone.

Brain health and cognitive function. Estrogen receptors are dense throughout the brain. Estradiol influences serotonin, dopamine, and acetylcholine signaling. Observational data and some clinical trial data support a role for estradiol in reducing dementia risk, though this remains an area of active research and I will not overstate the certainty here.

Sleep, mood, and temperature regulation. These are the symptoms most people associate with perimenopause and menopause, and estradiol addresses them directly through its effects on the hypothalamus and neurotransmitter regulation. The evidence here is strong and consistent.

Vulvovaginal and urogenital health. Genitourinary syndrome of menopause, which includes vaginal dryness, urinary urgency, recurrent UTIs (a very big deal!), and pain with intercourse, is directly related to estrogen decline. Local and systemic estrogen therapy both address this, though local is often used when systemic is not otherwise indicated.

Progesterone

If you have a uterus, progesterone is used alongside estradiol to protect the uterine lining from unopposed estrogenic stimulation, which can increase endometrial cancer risk. That is the protective clinical rationale. But progesterone is not only a uterine protection tool, so if you do not have a uterus, keep reading.

Micronized progesterone (bioidentical, not synthetic medroxyprogesterone acetate) has a meaningfully different safety and tolerability profile than the synthetic progestins used in the WHI. Micronized progesterone has demonstrated a neutral to potentially protective effect on breast tissue in observational data, whereas synthetic progestins, particularly medroxyprogesterone acetate, have been associated with increased breast cancer risk. These are not interchangeable compounds and the distinction is clinically significant. The long-term data on bioidentical progesterone continues to evolve, but the current evidence does not carry the same breast cancer signal as the synthetic progestin literature.

Beyond uterine protection, progesterone has calming and sleep-supporting properties through its conversion to allopregnanolone, which acts on GABA receptors. Women who struggle with sleep disruption, anxiety, and mood changes in perimenopause often notice meaningful improvement with progesterone specifically.

Testosterone

This is where the conversation in women's health has been both underserved and, in some corners, oversold, so I want to be thoughtful.

Testosterone is produced by the ovaries and adrenal glands in women throughout the lifespan. Levels begin declining in the late twenties and continue declining with age. This is not a post-menopause event. The ovaries have the potential to produce testosterone before and after they stop producing estradiol.

What the evidence supports for testosterone in women:

Low libido (hypoactive sexual desire disorder) is the only FDA-recognized indication, though it is not FDA-approved for women in the United States, meaning it is used off-label. Testosterone can potentially improve sexual desire, arousal, and satisfaction in women with documented low levels and associated symptoms. Now, because I am me.. I must tell you that all of these things…sexual desire, arousal, and satisfaction are multifactorial so if anyone is selling you promises… walk away. 

Emerging evidence also supports a role for testosterone in mood, energy, cognitive function, lean muscle maintenance, and bone density. Testosterone as a viable support for women is absolutely clinically meaningful. It is also misused, overdosed, and administered through delivery methods that produce supraphysiologic levels, which has its own set of consequences including androgenic side effects, SHBG suppression, and erythrocytosis at the high end.

I think it is incredibly important to say that use of testosterone in women has become a significant revenue driver in certain corners of the hormone therapy space. Pellet therapy in particular has a business model built on convenience and retention. You insert, you forget, you come back in three to four months. The problem is that pellets are non-titratable. Once they are in, the dose cannot be adjusted downward. Women are routinely overdosed. Supraphysiologic testosterone levels in women carry real risk, and the clinical justification for pellets over other delivery methods is weak. I believe in testosterone support tremendously but appropriately. 

Now, Back to Her

Here is where the answer gets specific, and I want to be transparent: what follows is a hypothetical clinical framework, not a personalized recommendation. I do not have her labs. I do not know her full history. What I can do is walk through the variables that would actually steer the conversation.

What we know:

She is 36 to 40 years old. She is cycling consistently, with a cycle length in the normal range. She is not on hormonal birth control or hormone therapy. She has had labs and understands them.

What we do not know:

Her symptom picture. Her hormone panel specifics. Her thyroid function. Her metabolic markers. Her stress physiology. Her body composition. Her digestive health. Her history with mood, sleep, and energy. Whether her labs show early hormonal shifts or whether everything looks appropriate for her age.

Why this matters:

A 36 to 40 year old woman with a regular cycle is not in menopause. She is not in clinical perimenopause, which is technically defined by cycle irregularity. However, she may be in a hormonal transition that standard labs either catch or miss depending on what was tested and when in her cycle it was drawn.

The fact that she is asking about hormone therapy at this age and stage suggests one of a few things: she is proactive and forward-thinking, she has symptoms that have not been attributed to hormones yet, or she has seen something in her labs that prompted the question. Any of these is a legitimate starting point.

Hypothetical Decision Tree

This is a simplified framework. Real clinical decision-making is not a flowchart, but this gives structure to the question of where hormone therapy fits for someone in her situation.

Branch 1: Labs are normal, no symptoms, cycles are regular and consistent.

Hormone therapy is not indicated as an immediate intervention. This is the time to document a baseline, not to initiate treatment. What is useful here is understanding her trajectory. A single lab draw is a snapshot. Comparing labs across cycles and over time tells a story. If this is where she sits, the work is optimization of the foundations: nutrition to support ovarian and adrenal function, training load appropriate to her recovery capacity, sleep, stress regulation, and gut health. These are not consolation prize recommendations. They are the variables that determine whether she remains hormonally healthy into her forties and beyond, or whether she starts declining faster than she should.

Branch 2: Labs are normal on standard testing, but she has symptoms.

This is the most common scenario I see. Fatigue, mood shifts, libido changes, disrupted sleep, and difficulty with body composition that does not respond to diet and training the way it used to. These symptoms in a cycling woman often precede lab changes. Standard hormone panels in a primary care or OB setting often look at day 3 FSH and estradiol, which can appear normal even when functional hormonal shifts are occurring. More comprehensive assessment, including a full thyroid panel, fasting insulin, SHBG, free testosterone, DHEA-S, cortisol rhythm, and a progesterone draw on day 19 to 21, tells a more complete story. If symptoms are present and labs are incomplete, the next step is better data, not hormone therapy.

Branch 3: Labs show early hormonal decline.

This is where the conversation about hormone therapy becomes relevant, but even here, the question is what specifically is declining and by how much. Low progesterone in the luteal phase is common in the late thirties and is often the first hormonal shift women experience. This may present as PMS, sleep disruption in the second half of the cycle, spotting before the period, and anxiety. Luteal phase progesterone support is a lower-intervention starting point than full HRT. Low testosterone with symptoms of low libido, fatigue, and mood changes may warrant a testosterone conversation, but at low doses with careful titration and injectable delivery as the first consideration over cream or pellets. Estrogen levels in a cycling woman are typically not the primary intervention target unless she is showing signs of estrogen dominance relative to progesterone, or unless labs suggest she is approaching a perimenopause pattern.

Branch 4: Cycle irregularity develops or FSH begins to rise.

This moves the conversation into perimenopause territory and changes the clinical calculus meaningfully. At that point, the benefits of estradiol and progesterone therapy expand and the timing window conversation becomes relevant. But she is not there yet based on what she shared.

So, How Does This Apply to Our Mystery Question Submission?

If you are the woman who submitted this question, this section is for you. And if this clinical picture sounds like yours, it applies to you too.

Here is what we know. You are between 36 and 40. You are cycling consistently with a cycle length in the normal range. You are not on hormonal birth control or any form of hormone therapy. You have had labs done and you understand them.

Here is what we do not know. I have not seen those labs. I do not know your symptom picture, your health history, your thyroid status, your metabolic function, your stress load, your body composition, or the fuller context that would move this from a general educational answer to something specific and actionable for you.

And that gap is important thing I can tell you right now.

Because the honest answer to the question of whether hormone therapy has a benefit for you, for you right now is: I nor any provider does not have enough information to say with just this alone. A consistent menstruation is a meaningful data point. It tells us your hypothalamic-pituitary-ovarian axis is doing its job at some level …I can’t really say what level though. But that is not nothing. A regular cycle does not tell us what your hormone levels look like throughout that cycle, what your labs actually showed systemically, whether you have symptoms you did not mention, or what else may be going on systemically that is worth addressing as a first step.

I need you, my amazing mystery woman, to know that you are asking great questions! Get informed now! What comes next for you is less about fitting into a category of women with this clinical picture and more about a direct conversation that looks at your full picture specifically.

If you are sitting with questions that feel too specific for a newsletter, that is exactly what our 1:1 strategy sessions are designed for. And if you are saying to yourself that your workplace should hear more about this, if you are part of a gym, a coaching company, or any group of women who you feel needs this level of discussion and the ability to ask questions, Fortify does public speaking, virtual webinars, and directed Q&As. We have been brought in virtually and we will be the first to say it has been so profound of an experience. If you want us for a wellness talk read more [HERE]

In the meantime, the anonymous form is still open. Your questions are shaping exactly what gets written next.

Ask Fortify anything, anonymously, right here.

In two weeks I will be publishing part two, which picks up right where this one leaves off. We are going into her second question delivery methods. How they work, how they differ, and how to choose one. 

Ask Fortify anything, anonymously, right here.